U.S. Supreme Court Backs Hikma In Vascepa Patent Dispute

Amman, June 5 (Petra)-- The U.S. Supreme Court has ruled that Hikma Pharmaceuticals' generic version of the cardiovascular drug Vascepa does not infringe patents held by Amarin Pharma, in a landmark decision that could reduce the exposure of generic drug manufacturers to patent litigation involving so-called "skinny labels." The ruling represents a significant achievement for Hikma Pharmaceuticals, one of Jordan's leading pharmaceutical companies, underscoring its strong competitive position in global markets and its ability to successfully navigate complex legal disputes with major international drugmakers.

The decision is also considered a major victory for the generic pharmaceutical industry, as it strengthens manufacturers' ability to introduce lower-cost alternatives to brand-name medicines while reducing legal risks associated with patent infringement claims.

According to Reuters, the unanimous 9-0 decision, authored by Justice Ketanji Brown Jackson, overturned a lower court ruling that had favored Amarin Pharma.

Legal experts say the judgment could limit future patent infringement lawsuits tied to "skinny labels," a regulatory mechanism that allows generic drugmakers to market medicines for approved uses that are not covered by existing patents while excluding patented indications from product labeling.

Generic drug manufacturers had warned that a ruling in Amarin's favor could have discouraged the development and marketing of lower-cost medicines, potentially contributing to higher drug prices in the United States.

The Supreme Court's decision is expected to provide greater legal certainty for generic pharmaceutical companies and reinforce competition in the U.S. healthcare market, helping expand access to affordable treatments for patients.

//Petra// MF

MENAFN05062026000117011021ID1111215714